Sarcoma care in the era of precision medicine
K Wallander, I Öfverholm, K Boye… - Journal of Internal …, 2023 - Wiley Online Library
Sarcoma subtype classification is currently mainly based upon histopathological
morphology. Molecular analyses have emerged as an efficient addition to the diagnostic …
morphology. Molecular analyses have emerged as an efficient addition to the diagnostic …
[HTML][HTML] Standardized and simplified reporting of next-generation sequencing results in advanced non-small-cell lung cancer: Practical indications from an Italian …
U Malapelle, A Delle Donne, F Pagni… - Critical reviews in …, 2024 - Elsevier
Molecular biomarker testing is increasingly becoming standard of care for advanced non-
small cell lung cancer (NSCLC). Tissue and liquid biopsy-based next-generation …
small cell lung cancer (NSCLC). Tissue and liquid biopsy-based next-generation …
[HTML][HTML] Evolving and Improving the Sustainability of Molecular Tumor Boards: The Value and Challenges
M Bartels, B Chibaudel, R Dienstmann, J Lehtiö… - Cancers, 2024 - mdpi.com
Simple Summary As the complexity of medical data and the specificity of cancer treatments
increase, the role of Molecular Tumor Boards (MTBs) becomes ever more crucial. These …
increase, the role of Molecular Tumor Boards (MTBs) becomes ever more crucial. These …
Molecular profiling of pediatric and young adult colorectal cancer reveals a distinct genomic landscapes and potential therapeutic avenues
A Busico, P Gasparini, E Rausa, L Cattaneo, F Bozzi… - Scientific Reports, 2024 - nature.com
Colorectal cancer (CRC) is a global health concern, and the incidence of early onset (EO)
CRC, has an upward trend. This study delves into the genomic landscape of EO-CRC …
CRC, has an upward trend. This study delves into the genomic landscape of EO-CRC …
Racial and ethnic inequities at the practice and physician levels in timely next-generation sequencing for patients with advanced non–small-cell lung cancer treated in …
PURPOSE Racial/ethnic inequities in next-generation sequencing (NGS) were examined for
patients with advanced non–small-cell lung cancer (aNSCLC) at the practice and physician …
patients with advanced non–small-cell lung cancer (aNSCLC) at the practice and physician …
Clinical impact of panel gene sequencing on therapy of advanced cancers of the digestive system: a retrospective, single center study
L Dreikhausen, A Klupsch, I Wiest, Q Xiao, N Schulte… - BMC cancer, 2024 - Springer
Background Panel gene sequencing is an established diagnostic tool for precision oncology
of solid tumors, but its utility for the treatment of cancers of the digestive system in clinical …
of solid tumors, but its utility for the treatment of cancers of the digestive system in clinical …
Impact of Comprehensive Genome Profiling on the Management of Advanced Non–Small Cell Lung Cancer: Preliminary Results From the Lung Cancer Cohort of the …
A Vitale, L Mastrantoni, J Russo, F Giacomini… - JCO Precision …, 2024 - ascopubs.org
PURPOSE The clinical and research FPG500 program (ClinicalTrials. gov identifier:
NCT06020625) is currently ongoing at the Fondazione Policlinico Universitario Agostino …
NCT06020625) is currently ongoing at the Fondazione Policlinico Universitario Agostino …
[HTML][HTML] Genetic alterations predict poor efficacy, outcomes and resistance to second-line osimertinib treatment in non-small cell lung cancer
H Bai, L Cheng, W Liu, WY Xu, Y Huo… - American Journal of …, 2024 - ncbi.nlm.nih.gov
The genetic heterogeneity of non-small cell lung cancer (NSCLC) may impact clinical
response and outcomes to targeted therapies. In second-line osimertinib treatment for …
response and outcomes to targeted therapies. In second-line osimertinib treatment for …
Is tumour sequencing effective for the identification of germline BRCA1/2 pathogenic variant carriers?
J Azzollini, I Capone, M Duca, A Vingiani… - Tumori …, 2024 - journals.sagepub.com
Introduction: Tumour BRCA1/2 sequencing has progressively increased along with the
expanding indications for poly (ADP-ribose) polymerase inhibitors. In our study, we …
expanding indications for poly (ADP-ribose) polymerase inhibitors. In our study, we …
Molecular tumor board decisions based on next generation sequencing for advanced gastrointestinal cancers
L Ostermann - 2024 - ub01.uni-tuebingen.de
1.1 GASTROINTESTINAL TUMORS Gastrointestinal (GI) tumors are a heterogenous group
of diseases. They comprise cancer of the esophagus, the stomach, and the intestine as well …
of diseases. They comprise cancer of the esophagus, the stomach, and the intestine as well …